Equities research analysts expect that West Pharmaceutical Services Inc. (NYSE:WST) will announce sales of $433.40 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for West Pharmaceutical Services’ earnings. The lowest sales estimate is $431.80 million and the highest is $435.00 million. West Pharmaceutical Services posted sales of $415.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 4.3%. The company is scheduled to issue its next earnings report on Thursday, April 25th.

On average, analysts expect that West Pharmaceutical Services will report full-year sales of $1.81 billion for the current year, with estimates ranging from $1.80 billion to $1.82 billion. For the next financial year, analysts expect that the firm will report sales of $1.95 billion, with estimates ranging from $1.93 billion to $1.97 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 14th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.72 by $0.01. West Pharmaceutical Services had a net margin of 12.05% and a return on equity of 15.89%. The business had revenue of $422.50 million during the quarter, compared to the consensus estimate of $432.38 million. During the same period in the previous year, the business earned $0.64 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis.

Separately, Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Saturday, January 12th.

WST traded up $1.48 during trading on Friday, hitting $114.43. 5,922 shares of the stock traded hands, compared to its average volume of 461,061. West Pharmaceutical Services has a twelve month low of $84.91 and a twelve month high of $125.09. The company has a market cap of $8.33 billion, a P/E ratio of 40.63, a P/E/G ratio of 3.58 and a beta of 1.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.15 and a quick ratio of 2.40.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Wednesday, April 17th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, April 16th. This represents a $0.60 annualized dividend and a dividend yield of 0.52%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.

Several large investors have recently made changes to their positions in WST. Hoover Financial Advisors Inc. increased its holdings in West Pharmaceutical Services by 0.3% in the first quarter. Hoover Financial Advisors Inc. now owns 42,208 shares of the medical instruments supplier’s stock valued at $4,651,000 after purchasing an additional 107 shares during the period. State of Alaska Department of Revenue boosted its position in West Pharmaceutical Services by 1.7% during the fourth quarter. State of Alaska Department of Revenue now owns 8,056 shares of the medical instruments supplier’s stock valued at $789,000 after acquiring an additional 131 shares during the last quarter. MetLife Investment Advisors LLC boosted its position in West Pharmaceutical Services by 0.3% during the fourth quarter. MetLife Investment Advisors LLC now owns 45,170 shares of the medical instruments supplier’s stock valued at $4,428,000 after acquiring an additional 148 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in West Pharmaceutical Services by 0.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 42,374 shares of the medical instruments supplier’s stock valued at $4,154,000 after acquiring an additional 159 shares during the last quarter. Finally, First Hawaiian Bank boosted its position in West Pharmaceutical Services by 6.7% during the fourth quarter. First Hawaiian Bank now owns 2,752 shares of the medical instruments supplier’s stock valued at $270,000 after acquiring an additional 172 shares during the last quarter. Institutional investors own 94.41% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

See Also: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.